Splintering AI trade; Dell’s forecast; Deere to report - what’s moving markets
RA'ANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ) announced Thursday that its PL-16 Viral Blocker nasal gel formulation demonstrated protective effects against H1N1 influenza virus in laboratory testing, according to a company press release. The micro-cap biotech, currently valued at just $11.46 million, is working to advance its respiratory protection technology despite reporting negative earnings of -$1.59 per share in its most recent financial period.
The in-vitro studies showed the gel prevented viral-induced cell damage and maintained high cell viability following viral exposure. The tests were conducted using cell models to evaluate the product's ability to block infection by multiple respiratory viruses.
Additional experiments revealed that the formulation works through a reversible physical mechanism rather than by permanently inactivating viruses. When the formulation was removed from virus particles that had been previously exposed to it, the viruses regained their infectivity, indicating the product functions as a temporary barrier.
"Demonstrating both strong viral blocking and reversibility is key to establishing the unique nature of our platform," said Tomer Izraeli, Chief Executive Officer of Polyrizon.
The company stated that the absence of cytotoxicity, combined with the reversible blocking effect, supports the formulation's safety profile. Future development plans include clinical studies pending regulatory approvals.
Polyrizon's technology, which the company calls its Capture and Contain platform, is designed to form a thin hydrogel barrier in the nasal cavity that can potentially block viruses and allergens from contacting nasal tissues.
The biotechnology company is developing intranasal products based on naturally occurring building blocks delivered as nasal sprays.
In other recent news, Polyrizon Ltd. reported significant progress in its research and regulatory efforts. The company announced promising preclinical results for its PL-14 Allergy Blocker, which demonstrated effective allergen blocking capabilities in laboratory tests. These findings indicated minimal allergen penetration, with only 1.07% passing through the barrier after one hour. Additionally, Polyrizon has submitted a comprehensive pre-submission package to the U.S. Food and Drug Administration for its PL-14 nasal spray, aimed at treating allergic rhinitis. This submission outlines the company's manufacturing plans, clinical development strategies, and regulatory pathways. In collaboration with the University of Parma, Polyrizon's preclinical study showed over 60% targeted deposition of the PL-14 formulation in the nasal vestibule. Furthermore, the company regained compliance with Nasdaq listing requirements, ensuring its continued trading on the Nasdaq Capital Market. These developments reflect Polyrizon's ongoing efforts to advance its intranasal products and maintain its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.